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nography. Her personal and family histories were not relevant to the
current disorder. Magnetic resonance imaging (MRI) showed a right
ovarianmasswithmarked enhancement on gadolinium-DTPA enhanced
T1-weighted images. As for serum tumor markers, the CA125 level was
31.8 U/ml, the CA 19-9 levelwas 6.8 U/ml, the carcinoembryonic antigen
(CEA) level was 0.6 ng/ml, and the alpha-fetoprotein (AFP) level was
4.4 ng/ml.
At laparotomy, a multilobulated mass measuring 5 cm in diameter
was found attached to the right fallopian tube by a short stalk. Some
tumor implants were noted in the serosal surface of the pouch ofIntroductionFemale adnexal tumor of probable Wolfﬁan origin (FATWO) was
ﬁrst reported in 1973 (Kariminejad and Scully, 1973). This rare neo-
plasm usually arises within the leaves of a broad ligament or is found
hanging from a ligament or a fallopian tube. These tumors are generally
thought to have a low malignant potential, since only 20 patients have
shown evidence of recurrence. Because few cases have been reported,
there are no ﬁrm recommendations regarding initial evaluation, treat-
ment, or adjuvant therapy. We report a case of FATWO that rapidly
progressed. The patient received multiple chemotherapy regimens,
including platinum-based treatment, and surgery for progressive
disease, but died 3 years later after the ﬁrst operation.
Case report
A 30-year-old Japanese woman (gravid 0, para 0) presented in
September 2008 to undergo routine screening by Pap test and pelvic
examination. She did not have any symptoms. A right ovarian mass),
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,Douglas. The patient underwent right salpingo-oophorectomy and
tumorectomy. After scraping with a piece of gauze, a total of 17 tumors
3 to 10 mm in diameter were removed from the pouch of Douglas. The
tumor was encapsulated and easily resectable within a cleavage plane.
Peritoneal washing cytology revealed a few atypical cells (Fig. 1a).
Histologic examination of the broad ligament tumor revealed a pre-
dominantly solid tumor punctured by numerous tubules and gland-like
structures. Cystic dilation and a sieve-like area were also observed. The
tubules were usually, but not invariably, small, well deﬁned, and lined
by a single layer of cuboidal epithelial cells with central nuclei and
conspicuous nucleoli (Fig. 1b). The tubal lumens and sieve-like spaces
frequently contained an eosinophilic substance. There were no areas
of hemorrhage or necrosis. The mitotic activity was brisk in the more
solid component. The peritoneal samples showed metastatic deposits
that were morphologically similar to those of the tumor of the broad
ligament. Immunohistochemical staining of the neoplasm was positive
for calretinin, inhibin, CD10, and vimentin and focally positive for
desmin and CD34. Staining for c-kit was negative.
The patient initially received chemotherapy with a combination o
paclitaxel and carboplatin (TC), but was allergic to paclitaxel. She then
received 3 cycles of carboplatin alone (area under the curve, 6). Howev-
er, follow-up MRI showed interval growth of the lesions and disease
progression 4 months after initial surgery. The second operation was
performed only 6 months after initial surgery. Total abdominal hys-
terectomy, bilateral oophorectomy, omentectomy, tumorectomy, and
biopsies of the pelvic and para-aortic lymph nodes were performed
Numerous tumor implants measuring 2 to 3 cm in diameter were
noted in the serosal surface of the bowel, the omentum, and the left
ovary. Recurrent tumors were also found in the pouch of Douglas
from which all tumors had been completely removed at the ﬁrst opera-
tion. Dissection of the tumor from the surrounding tissue was more
Fig. 1. a) Ascites ﬂuid showing medium sized atypical cells with round nuclei (Papanicolaou staining, ×400). b) Microphotograph of female adnexal tumor of probable Wolfﬁan origin.
Proliferation of tumor cells in a sieve-like pattern is seen (hematoxylin–eosin staining, ×200). c, d) Touch-imprint preparation showing clusters of atypical cells with clear nucleoli in
round nuclei (Papanicolaou staining, c; ×400, d; ×1000).
Table 1
Age at diagnosis of malignant FATWO.
Age No.
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ological examination were similar to those of the prior tumor. However,
the frequency of polymorphism was higher in the second tumor than in
the primary tumor. Cytopathological examination of touch imprint prep-
arations showedneoplastic cellswith round to oval nuclei, distinct nucle-
oli, and rosette-like architecture in some regions (Fig. 1c and d).
There was no evidence of lymph-node metastasis. At the second
laparotomy, additional immunohistochemical studies were done to
determine the CA125, calretinin, inhibin, CD10, estrogen receptor
(ER), progesterone receptor (PR), androgen receptor, and HER2 status.
The tumor was positive for CA125, calretinin, inhibin, CD10, estrogen
receptor, progesterone receptor, and androgen receptor and negative
for HER2. The patient was given oral medroxyprogesterone acetate
(MPA) 400 mg/day for 3 months as alternative chemotherapy. MRI re-
vealed disease progression, a mass measuring 2 cm in diameter in the
anterior aspect of the left iliopsoas muscle, and a tumor measuring
2 cm in diameter that had recurred in the anterior vaginal wall. A
mass accompanied by bleeding was found at the vaginal opening and
was therefore resected with the patient under local anesthesia. A
trans-vaginal tumorectomy was performed and the same feature was
seen on pathology. Therapy was then switched to pegylated liposomal
doxorubicin 50 mg/m2 every 4 weeks. She received only three cycles
of this regimen because interstitial pneumonia occurred as a severe
drug-induced side effect. At this time, MRI showed stable disease. The
patient then given irinotecan 50 mg/m2 on days 1 and 8 of a 28-day
cycle for three cycles, but treatment was ineffective and caused nausea.
Consequently, she received gemcitabine 700mg/m2 on days 1, 8, and 15
of a 28-day cycle for 8 cycles, without any adverse events. On comple-
tion of 8 cycles of treatment, MRI showed multiple masses in the
abdominal cavity, including the surface of the liver, and progressive
disease was diagnosed. The patient died of diffuse metastatic disease
3 years after the ﬁrst operation.−19 2
20–29 4
30–39 3
40–49 2
50–59 1
60–69 2
70–79 5
−80 1Discussion
FATWO was ﬁrst described in 1973 (Kariminejad and Scully, 1973).
These tumors are believed to be of Wolfﬁan (mesonephric) remnant
origin (Ramirez et al., 2002). About 80 cases of FATWO have beenreported; however, only 21 cases were associated with recurrence or
metastasis (malignant FATWO) (Lesin et al., 2009). A search of the
PubMed database using the keywords of “Wolfﬁan,” “origin,” and
“malignant,” revealed 12 studies published between 1985 and 2012.
These studies reported on 21 patients, including those included in the
references. Four patients were in their twenties at the time of diagnosis
of malignant FATWO, and other patients were aged 15 years (Steed
et al., 2004) and 18 years (Abbot et al., 1981), suggesting that many pa-
tients were young at the time of diagnosis (Table 1). The diagnosis is
based on a histological picture characterized by the presence of solid
areas of neoplastic epithelial cells punctured by distinct tubular struc-
tures, usually at sites where Wolfﬁan remnants exist.
Macroscopically, FATWO usually arises in the broad ligament or the
fallopian tube (Kariminejad and Scully, 1973). Typically, these tumors
are solid, nodular, or lobulated masses. On microscopic examination
FATWO was histopathologically characterized by closely packed, wind-
ing, branching, and anastomosing tubules, peripheral nuclei and central
cytoplasm, and a sieve-like patternwith hollow tubules varying in a size
and shapewith occasional cysts (Ramirez et al., 2002). Our case showed
these characteristic ﬁndings. Suggested criteria for malignancy were
proposed by Sivridis et al. (2005) and include large size (N100 mm),
hypercellularity, capsular invasion, capsule rupture, and demonstrable
tumor implants or metastases.
Tumor implants were described in 15 of the 21 reported cases of
malignant FATWO. Even in patients with tumor implants, prolonged
periods of up to 5 years or 8 years were sometimes required for recur-
rence, suggesting that the behavior of this tumor is consistent with a
Table 2
Progression-free survival of malignant FATWO with tumor implants.
Case no. Source, y Patient age, y Progression-free survival Site to recurrence MI Size of tumor (cm)
1 Debra S, 2011 24 6 weeks Pelvis Brisk 9.5 × 9.0 × 5.3 cm
2 Yiyan Liu, 2011 24 1 month Appendix Not reported Large left adnexal mass
3 Pedro T. Ramirez, 2002 38 3 years Pelvis
Liver
Not reported Paratubal nodule
4 Chaya J, 1992 47 4 years or more None Main tumor: infrequent
Peritoneal implant: frequent
20 × 25 cm
5 Irena Sheyn, 1999 60 5 years Liver surface Low 2/50 HPF 11 cm
6 Pedro T. Ramirez, 2002 71 1 years Liver Not reported 16 × 15 × 5 cm
7 E Sivridis, 2005 76 None (PD, died 4 months after operation) Peritoneum 0–2/10 HPF 20 × 18 × 8 cm
8 Dean Daya, 1994 81 None (PD, died 3 months after operation) Omentum 8–10/HPF 15 cm
Note. PD, progressive disease; MI, mitotic ﬁgure.
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at the ﬁrst operation had recurrence or metastasis within 1 year
(Table 2, Cases 1–3). In our patient, tumor implants were found in the
pouch of Douglas at the ﬁrst operation, and the tumor progressed rapid-
ly. In contrast, only 1 (Deen et al., 2007) of 7 patients without tumor
implants had recurrence within 1 year. In this patient, however, a
small amount of tumor was left behind, and no patient without tumor
implants who underwent complete resection had recurrence within
1 year. These ﬁndings suggest that patients with tumor implants or
residual tumor are at risk for early recurrence because the tumor
shows more malignant behavior than low malignant potential.
Generally, recurrent tumors showmoremarked atypia than primary
lesions, as well as higher mitotic indices (Lesin et al., 2009). These char-
acteristics are in agreement with our case. Cytologic descriptions have
been reported in 2 cases (Halushka and Ali, 2004; Tamiolakis and
Anastasiadis, 2007). In our patient, the cells obtained by peritoneal
washing were not consistent with the histologic characteristics of the
tumor. It was therefore difﬁcult to diagnose the lesion solely on the
basis of cytologic ﬁndings. On immunohistochemical analysis, the
tumor expressed calretinin, inhibin, CD10, and vimentin in accord
with the ﬁndings of previous studies.
Our patient had a poor response to chemotherapy and hormone
therapy. The roles of chemotherapy, radiotherapy, hormonal therapy,
and molecularly targeted therapy as adjuvant treatment remain
unknown. Ten patients were reported to receive chemotherapy. The
most commonly used drugs were cisplatin and cyclophosphamide. A
partial response to cyclophosphamide, doxorubicin, and cisplatin
(CAP) was reported in 1 patient (Abbot et al., 1981). One report de-
scribed a patient who was observed without chemotherapy because
tumor growthwas slow (Lesin et al., 2009). Our patient had progressive
disease despite treatment with 3 courses of paclitaxel plus carboplatin,
3 courses of irinotecan and 8 courses of gemcitabine.
Malignant FATWOhas been reported to be potentially hormone sen-
sitive because relapse occurred after pregnancy (Atallah et al., 2004).
Estrogen- or progesterone-receptor status was reported for 6 cases of
malignant FATWO, but there was no consistent tendency. On the
other hand, Wolfﬁan epithelium does not respond to cyclical hormonal
stimulation by nature, in contrast to Müllerian epithelium. One study
reported the use of leuprolide 22.5 mg with paclitaxel and carboplatin,
but the patient had progressive disease (Ramirez et al., 2002). In our
patient as well, MPA and leuprolide were ineffective, although the
tumor was positive for estrogen receptor, progesterone receptor, and
androgen receptor.
As for molecular targeted therapy, imatinib mesylate was reported
to delay recurrence in 2 patients with c-kit-positive tumors (Steed
et al., 2004). Among the 5 patients with malignant FATWO for whom
c-kit status was reported, c-kit was negative in the 3 other patients(Ramirez et al., 2002; Deen et al., 2007). In our patient, c-kit was not
expressed. Her-2 status was assessed in 3 cases, none of which were
positive.
Conclusion
In conclusion, malignant FATWO is characterized by diverse
features, including various disease courses and expressions of hormone
receptor and target oncogenes. However, recurrence can occur within
1 year in patients with tumor implants at initial surgery, suggesting
that this tumor has a higher malignant potential than a low malignant
potential tumor. Recommendations regarding adjuvant therapy are
currently unavailable. It appears that surgical debulking is the treatment
of choice for malignant FATWO, because adjuvant or salvage therapy
remains exploratory. Optional treatment may be effective in selected
patients.
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